New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
07:49 EDTEXELExelixis price target lowered to $9 from $11 at Stifel
Stifel cut its price target on Exelixis after the company announced that a committee had determined that its Phase III trial should continue based on lack of sufficient survival benefit to halt the trial,. The firm had expected the trial to be stopped early due to efficacy. Stifel notes that trials of competing drugs have been stopped early due to favorable results. However, it thinks the final results of Exelixis' trial could still be positive and keeps a Buy rating on the shares.
News For EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
07:54 EDTEXELLeerink a buyer of Alkermes, ImmunoGen, Incyte
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use